CCTG CE.6 / EORTC 26062-22061 (Perry trial)

CCTG CE.6 with EORTC 26062-22061 and TROG 08.02, trial NCT00482677, randomised 562 patients aged 65 or older (median 73) with newly diagnosed glioblastoma to short-course radiotherapy (40 Gy in 15 fractions) with or without concurrent and adjuvant temozolomide. Median overall survival was 9.3 versus 7.6 months (HR 0.67, 95% CI 0.56-0.80) and median progression-free survival 5.3 versus 3.9 months; with a methylated MGMT promoter, 13.5 versus 7.7 months (HR 0.53), and with an unmethylated promoter 10.0 versus 7.9 months (HR 0.75, 95% CI 0.56-1.01). Quality of life was similar in the two arms. Published by Perry and colleagues in NEJM in 2017. Two earlier trials had established the alternatives for older or frail patients: the Nordic trial (Malmström 2012; temozolomide alone or hypofractionated radiotherapy at least as good as standard six-week radiotherapy over age 60, and better over 70) and NOA-08 (Wick 2012; temozolomide alone non-inferior to radiotherapy alone, with MGMT methylation predicting who benefits from temozolomide).

Setting

Newly diagnosed glioblastoma, age 65 or older: short-course radiotherapy (40 Gy in 15 fractions) with concurrent and adjuvant temozolomide vs short-course radiotherapy alone

Phase

Phase 3

Sponsor

Canadian Cancer Trials Group / EORTC / TROG

Registry

NCT00482677

Headline result

OS 9.3 vs 7.6 months, HR 0.67 (95% CI 0.56-0.80).

Reported

2017

Enrolled

562

Replication

Single randomised trial of adding temozolomide to short-course radiotherapy; the Nordic and NOA-08 trials support hypofractionated radiotherapy or temozolomide alone in older patients, with MGMT status guiding the choice.

Outcomes

1top

In plain words

What these results mean for people, not percentages

562 people took part

Overall survival, age 65 or olderprimarysurvival endpoint

Median 9.3 vs 7.6 months with Short-course RT + temozolomide compared with Short-course RT alone; about 1.7 months longer for half the group.
A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
Put another way, the treated group had about 33 percent lower chance of the event at any given time (hazard ratio 0.67, likely range 0.56 to 0.8).

Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
These results apply to the people the trial enrolled: Newly diagnosed glioblastoma, age 65 or older: short-course radiotherapy (40 Gy in 15 fractions) with concurrent and adjuvant temozolomide vs short-course radiotherapy alone. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

562 participants enrolled.

Overall survival, age 65 or olderprimary

HR 0.67 (0.56 to 0.8) · p <0.001

Download

Source

Endpoint	Arm	n	Value	HR (95% CI)	p	Source
Overall survival, age 65 or olderprimary	Short-course RT + temozolomide	281	9.3 months	0.67 (0.56 to 0.8)	<0.001	link
Overall survival, age 65 or olderprimary	Short-course RT alone	281	7.6 months	0.67 (0.56 to 0.8)	<0.001	link

Replication

Single randomised trial of adding temozolomide to short-course radiotherapy; the Nordic and NOA-08 trials support hypofractionated radiotherapy or temozolomide alone in older patients, with MGMT status guiding the choice.